Intersect ENT Inc. (NASDAQ:XENT)’s share price was down 4.6% during trading on Thursday . The stock traded as low as $15.04 and last traded at $15.62, with a volume of 323,981 shares changing hands. The stock had previously closed at $16.37.

Several equities analysts have commented on XENT shares. Zacks Investment Research lowered Intersect ENT from a “hold” rating to a “sell” rating in a research report on Wednesday, April 27th. BTIG Research started coverage on Intersect ENT in a research report on Tuesday, July 12th. They set a “neutral” rating for the company. Wedbush reissued an “outperform” rating and set a $25.00 price objective on shares of Intersect ENT in a research report on Monday, July 18th. Finally, Canaccord Genuity reissued a “buy” rating on shares of Intersect ENT in a research report on Monday, July 18th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $24.20.

The company’s market capitalization is $429.93 million. The firm’s 50-day moving average is $14.27 and its 200 day moving average is $16.27.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.05. The company had revenue of $19.30 million for the quarter, compared to analysts’ expectations of $18.91 million. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.23) earnings per share. Analysts anticipate that Intersect ENT Inc. will post ($0.98) EPS for the current fiscal year.

In related news, VP James Stambaugh sold 3,977 shares of the company’s stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $17.00, for a total transaction of $67,609.00. Following the completion of the sale, the vice president now directly owns 27,977 shares in the company, valued at approximately $475,609. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kieran Gallahue acquired 8,000 shares of the firm’s stock in a transaction that occurred on Monday, May 16th. The shares were bought at an average price of $12.64 per share, with a total value of $101,120.00. Following the completion of the purchase, the director now directly owns 8,000 shares in the company, valued at $101,120. The disclosure for this purchase can be found here.

A number of large investors have added to or reduced their stakes in XENT. Mutual of America Capital Management LLC boosted its stake in Intersect ENT by 77.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 92,311 shares of the company’s stock worth $2,077,000 after buying an additional 40,311 shares during the period. Schroder Investment Management Group acquired a new stake in Intersect ENT during the fourth quarter worth approximately $6,845,000. Royce & Associates LLC boosted its stake in Intersect ENT by 15.7% in the fourth quarter. Royce & Associates LLC now owns 420,400 shares of the company’s stock worth $9,459,000 after buying an additional 56,900 shares during the period. RS Investment Management Co. LLC boosted its stake in Intersect ENT by 68.2% in the fourth quarter. RS Investment Management Co. LLC now owns 1,328,250 shares of the company’s stock worth $29,886,000 after buying an additional 538,720 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Intersect ENT by 36.2% in the fourth quarter. Wells Fargo & Company MN now owns 2,288,725 shares of the company’s stock worth $51,495,000 after buying an additional 607,788 shares during the period.

Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.